Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53-pulsed dendritic cell vaccine plus exemestane in recurrent/progressive breast cancer
2007-007596-16Phase 2Terminated
- Sponsor
- National Center for Cancer Immune Therapy
- Start
- Jun 2008
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mutant p53 peptide pulsed dendritic cell vaccine in breast adenocarcinoma and breast cancer, sponsored by National Center for Cancer Immune Therapy. Primary endpoints: Time to progression, Safety of dendritic cell vaccination in combination with exemestane and 2 more. Started Jun 2008; status: terminated.
02
Drugs
mutant p53 peptide pulsed dendritic cell vaccine
03
Conditions
breast adenocarcinomabreast cancer
Beyond the preview
Go deeper on 2007-007596-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007596-16.